Annovis Bio Inc
(ANVS)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 3,998 | 3,137 | 5,755 | 6,355 | 15,725 |
| TOTAL | $5,047 | $7,813 | $10,208 | $10,223 | $22,817 |
| Non-Current Assets | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Assets | $5,047 | $7,813 | $10,208 | $10,223 | $22,817 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 3,395 | 4,107 | 1,293 | 1,926 | 1,173 |
| Accrued Expenses | 663 | 763 | 2,986 | 1,639 | 901 |
| TOTAL | $4,057 | $4,870 | $4,279 | $3,565 | $2,074 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 2,740 | 6,297 | 13,680 | 0 | 0 |
| TOTAL | $2,740 | $6,297 | $13,680 | $N/A | $N/A |
| Total Liabilities | $6,797 | $11,167 | $17,959 | $3,565 | $2,074 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 13,054 | 11,171 | 11,011 | 10,262 | 9,012 |
| Common Shares | 1 | 1 | 1 | 1 | 1 |
| Retained earnings | -116,346 | -111,326 | -110,259 | -88,046 | -73,329 |
| TOTAL | $-1,751 | $-3,354 | $-7,751 | $6,658 | $20,743 |
| Total Liabilities And Equity | $5,046 | $7,813 | $10,208 | $10,223 | $22,816 |